Journey Medical stock edged up 1.1% to US$6.72 into Friday’s close, a modest move for what felt like a much louder earnings moment. The company just posted Q2 revenue of US$18.5m with Emrosi contributing US$8.1m, and reported a sharply smaller net loss of US$0.3m. On the headline numbers this looks less like a euphoric breakout and more like a measured re-rating as traders weigh a dermatology story that is still loss making but inching closer to the profitability line.

Impressed that Journey Medical is edging closer to break even but still uneasy about the ongoing losses and early stage profile? You may wish to consider screening for companies that are already profitable yet still small enough to grow using our 18 high quality undiscovered gems.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$18.51m vs. US$15.01m (up about 23%)
• Net Loss, Q2 2026 vs. Q2 2025: US$0.31m vs. US$3.80m (loss narrowed sharply)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.01 per share vs. loss of US$0.16 per share (loss per share reduced)
• Gross Margin, Q2 2026 vs. Q2 2025: 67% vs. 67% (stable year on year)

Prefer clean charts instead of another wall of financial tables and earnings headlines? See Journey Medical's full financial picture with an easy visual read on its path toward profitability in the company report for Journey Medical.

Journey Medical’s bull case leans on Emrosi leverage

Bulls argue that Journey Medical can turn Emrosi into a scaled rosacea franchise that lifts margins and gets the company to sustained profitability without heavy extra spend. Q2 gives some support to that story. Emrosi produced US$8.1m of net product revenue and roughly 20% sequential prescription growth, with June hitting an all time monthly high and July scripts around 14,000. More than 4,500 prescribers had written by quarter end, up from about 3,700 in Q1, which points to broadening reach rather than a narrow early adopter base. Gross margin stayed at 67% while SG&A of US$10.9m was lower than the prior year, which fits the operational leverage claim. Positive EBITDA and adjusted EBITDA for both the quarter and year to date, alongside US$25.6m of cash, show the model can approach break even when Emrosi executes well.

Bear case focuses on concentration, access and durability

Bears worry that Journey Medical is over reliant on Emrosi and a small product set, with payer friction and limited pipeline depth. The Q2 print does not remove that concern. Emrosi is already a major contributor and the company still reported a GAAP net loss of US$0.3m, so true profitability is not yet in hand. Management highlighted remaining prior authorization hurdles and multi step edits despite three GPO contracts and only 38% of 192m covered lives on higher quality terms. That supports the view that prescription growth might not fully translate into clean, repeatable revenue. Legacy brands like QBREXZA show some volume variability and Eurax is very early. Recent going concern language and modest marketing increases plus new reps in the field keep execution and liquidity risk on the table, even with positive EBITDA.

With Journey Medical still reporting losses and leaning on US$25.6m of cash, many investors want to stress test how long that runway can support growth plans. Check the full balance sheet, liquidity and cash burn picture in our financial health analysis of Journey Medical stock.

Stay Ahead With Simply Wall St

If Journey Medical’s march toward break even has your attention, register for free with Simply Wall St and add it to your Watchlist so you can track price against fair value and watch how each earnings report shifts the risk reward set up. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter to your thesis. For a longer term view, tap into the Community to see how other investors are thinking about catalysts, risks and turning points. That way you spot potential inflection points early, keep your decisions grounded in data and stay a step ahead of the market.

Seeking Alternatives Beyond Journey Medical?

Fresh ideas get snapped up fast. Some stocks are already building momentum while they are still under the radar for now. Research opportunities thoroughly before they attract wider attention and consider timely action based on your analysis.

• Identify companies with strong balance sheets before they are potentially re rated by the market by reviewing the curated list of solid balance sheet and fundamentals stocks (50 results).
• Explore potential income and price stability in one step by scanning the hand picked 10 dividend fortresses.
• Monitor developments in the infrastructure space by tracking the focused 38 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.